Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johansen, H. K.
Right arrow Articles by Frimodt-Møller, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansen, H. K.
Right arrow Articles by Frimodt-Møller, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 973-980
© 2000 The British Society for Antimicrobial Chemotherapy

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo

Helle Krogh Johansen, Thøger Gorm Jensen, Ram Benny Dessau, Bettina Lundgren and Niels Frimodt-Møller*

Department of Clinical Microbiology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark

The combination of ß-lactam antibiotics and macrolides is often recommended for the initial empirical treatment of acute pneumonia in order to obtain activity against the most important pathogens. Theoretically, this combination may be inexpedient, as the bacteriostatic agent may antagonize the effect of the bactericidal agent. In this study, the possible interaction between penicillin and erythromycin was investigated in vitro and in vivo against four clinical isolates of Streptococcus pneumoniae with MICs of penicillin ranging from 0.016 to 0.5 mg/L and of erythromycin from 0.25 to >128 mg/L. In vitro time–kill curves were generated with clinically relevant concentrations of penicillin (10 mg/L) and erythromycin (1 mg/L), either individually or in combination. Antagonism between penicillin and erythromycin was observed for the four isolates. In vivo interaction was investigated in the mouse peritonitis model. After intraperitoneal inoculation, penicillin and erythromycin were given either individually or in combination. For two of the four isolates, mortality was significantly higher in the groups treated with the combination of penicillin and erythromycin than in the groups treated with penicillin alone [32/36 (86%) vs 3/12 (25%), P < 0.05; and 24/36 (67%) vs 3/12 (25%), P < 0.05, respectively]. Using the mouse peritonitis model, in vivo time–kill curves showed that there was antagonism between erythromycin and penicillin for the examined isolate. The antagonism demonstrated in vitro and in vivo between penicillin and erythromycin suggests that ß-lactam antibiotics and macrolides should not be administered together unless pneumococcal infection is ruled out.

* Corresponding author. Tel: +45-32-68-36-47; Fax: +45-32-68-38-73; E-mail: nfm{at}ssi.dk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
S. P. Falk, A. T. Ulijasz, and B. Weisblum
Differential Assay for High-Throughput Screening of Antibacterial Compounds
J Biomol Screen, December 1, 2007; 12(8): 1102 - 1108.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
M. Paul, A. D. Nielsen, A. Gafter-Gvili, E. Tacconelli, S. Andreassen, N. Almanasreh, E. Goldberg, R. Cauda, U. Frank, L. Leibovici, et al.
The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis
Eur. Respir. J., September 1, 2007; 30(3): 525 - 531.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Aspa, O. Rajas, F. Rodriguez de Castro, M. C. Huertas, L. Borderias, F. J. Cabello, J. Tabara, S. Hernandez-Flix, A. Martinez-Sanchis, and A. Torres
Impact of initial antibiotic choice on mortality from pneumococcal pneumonia
Eur. Respir. J., May 1, 2006; 27(5): 1010 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. Shefet, E. Robenshtok, M. Paul, and L. Leibovici
Empirical Atypical Coverage for Inpatients With Community-Acquired Pneumonia: Systematic Review of Randomized Controlled Trials
Arch Intern Med, September 26, 2005; 165(17): 1992 - 2000.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. J. Oosterheert, M. J. M. Bonten, E. Hak, M. M. E. Schneider, and I. M. Hoepelman
How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review
J. Antimicrob. Chemother., October 1, 2003; 52(4): 555 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Garcia Vazquez, J.A. Martinez, J. Mensa, F. Sanchez, M.A. Marcos, A. de Roux, and A. Torres
C-reactive protein levels in community-acquired pneumonia
Eur. Respir. J., April 1, 2003; 21(4): 702 - 705.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Lin, R. J. Stanek, and M. A. Mufson
Lack of Synergy of Erythromycin Combined with Penicillin or Cefotaxime against Streptococcus pneumoniae In Vitro
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1151 - 1153.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.